Key result
Empagliflozin plus Alda-1 improves cardiac function and exercise tolerance over empagliflozin alone in HFpEF mice.
Why the study?
Hyperglycemia-induced 4HNE accumulation mediates cardiotoxicity in diabetic hearts, suggesting that lowering 4HNE by decreasing generation or increasing ALDH2-mediated detoxification could ameliorate diabetes-associated HFpEF.
Does the combination of empagliflozin and Alda-1 improve cardiac function and exercise tolerance in mice with diabetes-associated HFpEF?
Does the combination of empagliflozin and Alda-1 improve cardiac function and exercise tolerance in mice with diabetes-associated HFpEF?
Combining an SGLT2 inhibitor with an ALDH2 activator synergistically improves cardiac function in a preclinical model of diabetes-associated HFpEF.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for diabetes-associated HFpEF; extends preclinical evidence for ALDH2 activation with SGLT2 inhibition.
To ameliorate diabetes mellitus-associated heart failure with preserved ejection fraction (HFpEF), we plan to lower diabetes-mediated oxidative stress-induced 4-hydroxy-2-nonenal (4HNE) accumulation by pharmacological agents that either decrease 4HNE generation or increase its detoxification.A cellular reactive carbonyl species (RCS), 4HNE, was significantly increased in diabetic hearts due to a diabetes-induced decrease in 4HNE detoxification by aldehyde dehydrogenase (ALDH) 2, a cardiac mitochondrial enzyme that metabolizes 4HNE. Therefore, hyperglycemia-induced 4HNE is critical for diabetes-mediated cardiotoxicity and we hypothesize that lowering 4HNE ameliorates diabetes-associated HFpEF. We fed a high-fat diet to ALDH2*2 mice, which have intrinsically low ALDH2 activity, to induce type-2 diabetes. After 4 months of diabetes, the mice exhibited features of HFpEF along with increased 4HNE adducts, and we treated them with vehicle, empagliflozin (EMP) (3 mg/kg/d) to reduce 4HNE and Alda-1 (10 mg/kg/d), and ALDH2 activator to enhance ALDH2 activity as well as a combination of EMP + Alda-1 (E + A), via subcutaneous osmotic pumps. After 2 months of treatments, cardiac function was assessed by conscious echocardiography before and after exercise stress. EMP + Alda-1 improved exercise tolerance, diastolic and systolic function, 4HNE detoxification and cardiac liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) pathways in ALDH2*2 mice with diabetes-associated HFpEF. This combination was even more effective than EMP alone. Our data indicate that ALDH2 activation along with the treatment of hypoglycemic agents may be a salient strategy to alleviate diabetes-associated HFpEF.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2022) studied Diabetes-Associated HFpEF (n=40). Empagliflozin + Alda-1 vs. Vehicle, Empagliflozin alone, or Alda-1 alone was evaluated on Cardiac function and exercise tolerance. The combination of empagliflozin and Alda-1 improved exercise tolerance, diastolic and systolic function, and 4HNE detoxification in mice with diabetes-associated HFpEF more effectively than empagliflozin alone.
Synapse has enriched 10 related papers. Consider them for comparative context: